Radioiodinated metaiodobenzylguanidine (MIBG): Radiochemistry, biology, and pharmacology

Seminars in Nuclear Medicine

Volumn 41, Issue 5, 2011, Pages 324-333

  Vallabhajosula, Shankar ^a   Nikolopoulou, Anastasia ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 125; (3 IODOBENZYL)GUANIDINE I 131; 3 IODOBENZOIC ACID; AMMONIUM SULFATE; BRETYLIUM; GUANETHIDINE; IODOHIPPURIC ACID; NORADRENALIN;

DOSIMETRY; DRUG HALF LIFE; DRUG METABOLISM; ELECTROPHILICITY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEOPHILICITY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; QUALITY CONTROL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION RESPONSE; RADIOACTIVITY; RADIOBIOLOGY; RADIOCHEMISTRY; RADIOIODINATION; REVIEW; SOLID PHASE EXTRACTION; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

3-IODOBENZYLGUANIDINE; ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; QUALITY CONTROL; RADIOCHEMISTRY; RADIOMETRY;

EID: 79960903950     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.05.003     Document Type: Review

References (66)

1. 131I]iodobenzylguanidine. J Nucl Med 21:349-353, 1980 (Pubitemid 10100562)
2. 131I] meta-iodobenzylguanidine: Concise communication. J Nucl Med 22:358-364, 1981
3. Nakajo M, Shapiro S, Copp J, et al: The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 4:672-682, 1983 (Pubitemid 13016087)
4. Sisson JC, Frager MS, Valk TW, et al: Scintigraphic localization of pheochromocytoma. N Engl J Med 305:12-17, 1981 (Pubitemid 11071190)
5. McEwan AJ, Shapiro B, Sisson JC, et al: Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumours. Semin Nucl Med 15:132-153, 1985
6. 123I-Meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis. J Clin Endocrinol Metab 95:2596-2606, 2010
7. 131I-Metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. Semin Nucl Med 40:153-163, 2010
8. Melograna J: Iobenguane sulfate, I-131 (CIS-US) 03/24/1994 approval (tumor management): Pharmacology/toxicology. NDA20-084, August 13, 1993
9. Draximage® MIBG iobenguane I 131 injection, USP (package insert). Kirkland, Quebec, Canada, Draximage, Inc, March 2006
10. Iobenguane sulfate I 131 injection diagnostic: For intravenous use (pack insert). Bedford, MA, CISUS, Inc., July 1999
11. Kline RC, Swanson DP, Wieland DM, et al: Myocardial imaging in man with I-123 meta iodobenzylguanidine. J Nucl Med 22:129-132, 1981 (Pubitemid 11143204)
12. Raffel DM, Wieland DM: Development of MIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Img 3:111-116, 2010
13. Agostini D, Verberne HJ, Hamon M, et al: Cardiac 123I-MIBG scintigraphy in heart failure. Q J Nucl Med Mol Imag 52:369-377, 2008
14. 131I]iodobenzylguanidine. Appl Radiat Isot 44:621-628, 1993
15. Mairs RJ, Gaze MN, Watson DG, et al: Carrier-free I-131 meta-iodobenzylguanidine: Comparison of production from meta- diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine. Nucl Med Commun 15:268-274, 1994 (Pubitemid 24119872)
16. Beierwalters WH, Wieland DM, Yu T, et al: Adrenal imaging agents: Rationale, synthesis, formulation, and metabolism. Semin Nuci Med 7:5-21, 1978 (Pubitemid 8282217)
17. Burnstock G, Costa M: Adrenergic Neurons. New York, NY, John Wiley and Sons, 1975, pp 35-36
18. Liberman LM, Beierwalters WH, Conn JW, et al: Diagnosis of adrenal disease by visualization of human adrenal glands with 19-iodocholesterol. N Engl J Med 285:1387-1393, 1971
19. Short JH, Darby TD: Sympathetic nervous system blocking agents: III - Derivatives of benzylguanidine. J Med Chem 10:833-840, 1967
20. Kabalka GW, Varma RS: The synthesis of radiolabeled compounds via organometallic intermediates. Tetrahedron 45:6601-6621, 1989
21. Kabalka GW, Mereddy AR: A facile no-carrier-added radioiodination procedure suitable for radiolabeling kits. Nucl Med Biol 31:935-938, 2004 (Pubitemid 39297691)
22. Eersels JLH, Travis MJ, Herscheid JDM: Manufacturing I-123-labelled radiopharmaceuticals: Pitfalls and solutions. J Label Compd Radiopharm 48:241-257, 2005 (Pubitemid 40547334)
23. 131I-labelled human growth hormone of high specific radioactivity. Biochem J 89:114-123, 1963
24. 125I containing acylating agent. Biochem J 133:529-538, 1973
25. +) assisted nucleophilic exchange: Application and mechanistic approach, in EmramAM(ed): New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control. New York, NY, Plenum Press, 1991
26. Mertens JJR, Vanryckeghem W, Carlsen L: Cu(I) Supported Isotopic Exchange of Arylbound Iodide, New Future for Fast High Yield Labelling: Progress in Radiopharmacy. The Hague, the Netherlands, Martinus- Nijhoff, 1986, pp 101-109
27. Mangner JT, Wu J-L, Wieland DM: Solid-phase exchange radioiodination of aryl iodides: Facilitation by ammonium sulfate. J Org Chem 47:1484-1488, 1982
28. Mangner JT, Anderson-Davis H, Wieland DM, et al: Synthesis of I-131 and I-123 metaiodobenzylguanidine for diagnosis and treatment of pheochromocytoma. J Nucl Med 24:118, 1983
29. 131I-MIBG with high specific activity for radiotherapeutical purposes. J Label Compd Radiopharm 21:1130, 1984
30. 123I-m-iodobenzylguanidine. Appl Radiat Isot 39:939-942, 1988
31. Wafelman AR, Konings MCP, Hoefnagel CA, et al: Synthesis, radiolabeling, and stability of radioiodinated m-iodobenzylguanidine, a review. Apply Radiat Isot 45:997-1007, 1995
32. 123I-labelled metaiodobenzylguanidine. J Radioanal Nucl Chel Lett 96:97, 1985
33. 131I]MIBG. Appl Radiat Isot 38:303-304, 1987
34. Prabhakar G, Mehra K, Ramamoorthy N, et al: Evaluation of radioiodination of meta-iodobenzylguanidine catalyzed by in situ generated Cu(I) and directly added Cu(II). Appl Radiat Isot 50:1011-1014, 1999 (Pubitemid 29189600)
35. 131I]- meta-iodobenzylguanidine (MIBG) using Cu(I) generated in situ by sodium metabisulphite. Appl Radiat Isot 43:737-740, 1992
36. 131I-MIBG for clinical use. Appl Radiat Isot 69:63-67, 2011
37. Vaidyanathan G: Meta-iodobenzylguanidine and analogs: Chemistry and biology. Q J Nucl Med Mol Imaging 52:351-368, 2008
38. 123I-MIBG and preliminary clinical evaluation in patients with ventricular arrhythmias. Nucl Med Commun 20:537-545, 1999
39. 123I-MIBG. J Label Compd Radiopharm 42:653-661, 1999
40. Hunter DH, Zhu X: Preparation of radiolabeled haloaromatics polymerbased intermediates. WO Patent 99/18053, US Patent 6,461,585 (1999)
41. 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution. Cancer Biother Radiopharma 25:299-308, 2010
42. Smets LA, Loesberg C, Janssen M, et al: Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SKNSH cells. Cancer Res 49:2941-2944, 1989 (Pubitemid 19148630)
43. Bomanji J, Levison DA, Flatman WD, et al: Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: A histopathological comparison. J Nucl Med 28:973-978, 1987 (Pubitemid 17086816)
44. Mairs RJ, Boyd M: Optimizing MIBG therapy of neuroendocrine tumors: Preclinical evidence of dose maximization and synergy. Nucl Med Biol 35:9-20, 2008
45. Jaques S, Tobes MC, Sisson JC, et al: Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 26:539-546, 1984 (Pubitemid 15190718)
46. Tobes MC, Jaques S, Wieland DM, et al: Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26:897-907, 1985 (Pubitemid 16001493)
47. 131I-MIBG: Evaluation of a novel preparation of a therapeutic radiopharmaceutical. J Nucl Med 36:1088-1095, 1995
48. 131I-meta-iodo-benzyl guanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer 70:97-101, 1994
49. Carlin S, Mairs RJ, McCluskey AG, et al: Development of a real-time polymerase chain reaction assay for prediction of the uptake of [131I]meta-iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 9:3338-3344, 2003 (Pubitemid 37082728)
50. Sisson JC, Wieland DM, Sherman P, et al: Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 28:1620-1624, 1987 (Pubitemid 17158138)
51. Nakajo M, Shimabukuro K, Yoshimura H, et al: Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 27:84-89, 1986 (Pubitemid 17023175)
52. Sisson J, Shapiro B, Meyers L, et al: Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625-1636, 1987 (Pubitemid 17158139)
53. Rabinovitch MA, Rose CP, Schwab AJ, et al: A method of dynamic analysis of iodine-123-meta-iodobenzylguanidine scintigrams in cardiac mechanical overload hypertrophy and failure. J Nucl Med 34:589-600, 1993 (Pubitemid 23115659)
54. Sisson JC, Lynch JJ, Johnson J, et al: Scintigraphic detection of regional disruption of adrenergic neurons in the heart. Am Heart J 116:67-76, 1988
55. Minardo JD, Tuli MM, Mock BH, et al: Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 78:1008-1019, 1988
56. Leung A, Shapiro B, Hattner R, et al: Specificity of radioiodinated MIBG for neutral crest tumors in childhood. J Nucl Med 38:1352-1357, 1997 (Pubitemid 27386188)
57. 131I]meta- iodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma. Eur J Cancer 31A:576-581, 1995
58. Babich JW, Graham W, Fischman AJ: Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells. Eur J Nucl Med 24:538-543, 1997 (Pubitemid 27239213)
59. 125I]iodobenzylguanidine on the human neuroblastoma cell lines SKNSH and SKN-LO. Cancer Res 48:2993-2997, 1988
60. 123I]MIBG in rats. Nucl Med Commun 9:663-667, 1988
61. 123I-MIBG: An initial clinical study in patients with phaeochromocytoma. Nucl Med Commun 21:437-440, 2000
62. 131I]meta-iodobenzylguanidine, for the treatment of tumours transfected with the noradrenaline transporter gene. Lett Drug Des Disc 1:50-57, 2004
63. 123I-metaiodobenzyl-guanidine for the assessment of cardiac sympathetic nerve activity. Eur J Nucl Med Mol Imaging 33:483-490, 2006
64. Coleman RE, Stubbs JB, Barrett JA, et al: Radiation dosimetry, pharmacokinetics, and safety of Ultratrace-iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. Cancer Biother Radiopharma 24:469-475, 2009
65. Mangner TJ, Tobes MC, Wieland DW, et al: Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma. J Nucl Med 27:37-44, 1986 (Pubitemid 17023167)
66. Iobenguane sulfate I 131 injection (NDA 020084), package insert, revised September 2009. Bedford, MA, Pharmalucence, Inc